Pharmacokinetics and safety of Z-321, a novel specific orally active prolyl endopeptidase inhibitor, in healthy male volunteers

Journal of Clinical Pharmacology

Volumn 39, Issue 5, 1999, Pages 462-470

  Umemura, Kazuo ^a   Kondo, Kazunao ^a   Ikeda, Yasuhiko ^a   Nishimoto, Masahiko ^a   Hiraga, Yoshihiro ^b   Yoshida, Yasuhisa ^b   Nakashima, Mitsuyoshi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b ZERIA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 INDANYLACETYL) 4 (1 PYRROLIDINYLCARBONYL)THIAZOLIDINE; DRUG METABOLITE; N BENZYL 2 [[2 (HYDROXYACETYL) 1 PYRROLIDINYL]CARBONYL] 1 PYRROLIDINECARBOXAMIDE; PROLYL ENDOPEPTIDASE INHIBITOR; SULFOXIDE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; DRUG BIOAVAILABILITY; DRUG DETERMINATION; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TOLERANCE; ENZYME ACTIVITY; ENZYME INHIBITION; HEADACHE; HUMAN; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PLASMA CLEARANCE; SKIN MANIFESTATION; URINE LEVEL; VOMITING;

ADULT; CHOLINESTERASES; HUMANS; MALE; NEUROPEPTIDES; PILOT PROJECTS; PROTEASE INHIBITORS; PYRROLIDINES; THYROID HORMONES;

EID: 0032799595     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Tanaka Y, Niwa S, Nishioka H, Yamanaka T, Torizuka M, Yoshinaga K, Kobayashi N, Ikeda Y, Arai H: New potent prolyl endopeptidase inhibitors: synthesis and structure-activity relationships of indan and tetralin derivatives and their analogues. J Med Chem 1994;37:2071-2078.
2. Mazurek MF, Beal MF, Bird ED, Martin JB: Vasopressin in Alzheimer's disease: a study of postmortem brain concentrations. Annals of Neurology 1986;20:665-670.
3. Fujiyoshi K, Suga H, Okamoto K, Nakamura S, Kameyama M: Reduction of arginine-vasopressin in the cerebral cortex in Alzheimer type senile dementia. J Neurol Neurosurg Psychiat 1987;50:929-932.
4. Aoyagi T, Wada T, Nagai M, Kojima F, Harada S, Takeuchi T, Takahashi H, Hirokawa K, Tsumita T: Deficiency of kallikrein-like enzyme activities in cerebral tissue of patients with Alzheimer's disease. Experientia 1990;46:94-97.
5. Miura N, Shibata S, Watanabe S: Increase in the septal vasopressin content by prolyl endopeptidase inhibitors in rats. Neuroscience Letters 1995;196:128-130.
6. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T: A pharmacokinetic analysis program (multi) for microcomputer. J Pharm Dyn 1981;4:879-885.
7. Yamaoka K, Nakagawa T, Uno T: Statistical moments in pharmacokinetics. J Pharmacokin Biopharm 1978;6:547-558.
8. Umemura K, Kondo K, Ikeda Y, Kobayashi T, Urata Y, Nakashima M: Pharmacokinetics and safety of JTP-4819, a novel specific orally active prolyl endopeptidase inhibitor, in healthy male volunteers. Br J Clin Pharmacol 1997;43:613-618.
9. Imai H. Kodama T, Yasuda T, Nakamoto Y, Miura AB: Inverse relationship between serum cholinesterase activity and the administration of cyclophosphamide: an index of cyclophosphamide therapy. Nephrology Dialysis Transplantation 1994;9:1240-1249.
10. Belfiore F, Lo Vecchio L, Napoli E: Serum enzymes in diabetes mellitus. Clin Chem 1973;19:447-452.
11. Nomura F, Ohnishi K. Koen H, Hiyama Y, Nakayama T, Itoh Y, Shirai K, Saitoh Y, Okuda K: Serum cholinesterase in patients with fatty liver. J Clin Gastroenterol 1986;8:599-602.
12. McQueen MJ: Clinical and analytical considerations in the utilization of cholinesterase measurements. Clin Chimica Acta 1995;237:91-105.
13. Neitlich HW: Increased plasma cholinesterase activity and succinylcholine resistance: a genetic variant. J Clin Invest 1966;45:380-387.
14. Hada T, Yamawaki M, Moriwaki Y, Tamura S, Yamamoto T, Amuro Y, Nabeshima K, Higashino K: Hypercholinesterasemia with isoenzymic alteration in a family. Clin Chem 1985;31:1997-2000.
15. Yamamoto K, Morito F, Setoguchi Y, Fujii S, Kariya T, Sakai T: Characterization of serum cholinesterase in familial hyper-cholinesterasemia associated with an isozyme variant band. Gastroenterologia Japonica 1987;22:187-193.
16. Krause A, Lane AB, Jenkins T: A new high activity plasma cholinesterase variant. J Med Genet 1988;25:677-681.
17. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA: Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985;38:402-408.
18. Burbach JP, Kovacs GL, de Wied D, van Nispen JW, Greven HM: A major metabolite of arginine vasopressin in the brain is a highly potent neuropeptide. Science 1983;221:1310-1312.
19. O'Leary R, O'Connor B: Thyrotropin-releasing hormone. J Neurochem 1995;65:953-963.
20. Soeda S, Ohyama M, Yamakawa N, Shimeno H, Nagamatsu A: Two molecular species of proline endopeptidase in human plasma: isolation and characterization. Chem Pharm Bull 1984;32:4061-4069.